NCT07331155 2026-03-09
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
Clinical Trials
8 trialsNCT07390383 2026-02-09
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Not yet recruiting
NCT03736889 2025-12-17
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
BeOne Medicines
Phase 2 Recruiting
NCT05014828 2025-08-24
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT04716634 2025-03-25
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT06032845 2025-02-27
CASTLE-11
Fudan University
Phase 2 Recruiting
NCT05582031 2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2 Withdrawn
NCT05841134 2023-05-09
Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting